Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.30+0.09 (+2.14%)
Close on Nov 13, 2026Market cap $344.88MP/E –Yield –
Atea Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Atea Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$171.64M. For fiscal 2025 it was -$180.47M. The highest annual figure on record is $138.41M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$180.47M | – |
| FY2024 | Dec 31, 2024 | -$192.53M | – |
| FY2023 | Dec 31, 2023 | -$163.75M | – |
| FY2022 | Dec 31, 2022 | -$130.39M | -194.2% |
| FY2021 | Dec 31, 2021 | $138.41M | – |
| FY2020 | Dec 31, 2020 | -$11.01M | – |
| FY2019 | Dec 31, 2019 | -$14.59M | – |
| FY2018 | Dec 31, 2018 | -$9.46M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$33.91M | – |
| Q2 FY2026 | Jun 30, 2026 | -$35.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$54.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.47M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.80M | -132.8% |
| Q3 FY2022 | Sep 30, 2022 | -$16.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.25M | -470.9% |
| Q1 FY2022 | Mar 31, 2022 | -$42.17M | -237.5% |
| Q4 FY2021 | Dec 31, 2021 | $121.19M | +486.8% |
| Q3 FY2021 | Sep 30, 2021 | -$22.14M | – |
| Q2 FY2021 | Jun 30, 2021 | $8.70M | – |
| Q1 FY2021 | Mar 31, 2021 | $30.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.04M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.75M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.77M | – |
See a number that looks wrong?